Original Research Article

A study of Acinetobacter infections in a tertiary care hospital in Northeast India

Swarnatrisha Saha, Ksh Mamta Devi*, Shan Damrolien, Kh Sulochana Devi

Department of Microbiology, Regional Institute of Medical Sciences, Imphal, Manipur, India

Received: 29 March 2018
Accepted: 27 April 2018

*Correspondence:
Dr. Ksh Mamta Devi,
E-mail: ssaha1743@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Acinetobacter is an important opportunistic pathogen and is a common cause of hospital acquired infections. Acinetobacter infections are often extremely difficult to treat because of their widespread resistance to the major groups of antibiotics. The study was conducted to determine prevalence and antibiotic susceptibility pattern of Acinetobacter species isolated from various clinical samples.

Methods: Clinical specimens over a period of 2yrs from May 2015 to April 2017 were collected from the patients attending the hospital. Acinetobacter species isolates were identified, and antibiotic susceptibility test was done following standard operative procedures.

Results: From 9979 clinical specimens, 3715 were positive for significant bacterial growth of which 111 (2.9%) were culture positive for Acinetobacter spp. Among 111 isolates 109 (98.2%) isolates were Acinetobacter baumannii and 2 (1.8%) were Acinetobacter lwoffii. Maximum isolates were isolated from urine samples 36 (32.4%) and majority of the isolates were from wards (56.7%) giving a probability of increased hospital acquired infections. Maximum resistance was shown by cefipime (80.1%). Imipenem and Meropenem shows resistance of 25.3% and 29.7% respectively. ICU isolates showed extensive resistance in comparison to wards and OPD.

Conclusions: Increasing trend of resistance pattern to a large range of antibiotics is a matter of concern. To avoid resistance, antibiotics should be used judiciously, and empirical therapy should be determined for each hospital according to the resistance rates of the hospital. Infection with MDR Acinetobacter species is independently associated with high mortality, emphasizing the need for aggressive infection control strategies.

Keywords: Antibiotic susceptibility, Empirical therapy, Hospital acquired infections, Infection control strategies

INTRODUCTION

Acinetobacter spp. are Gram negative, strictly aerobic, non-fastidious, non-fermenting encapsulated coccobacilli causing mostly hospital acquired infections. According to most recent scientific literature, Acinetobacter spp. are the second most common non-fermenting gram negative pathogen isolated from clinical samples after Pseudomonas aeruginosa. Acinetobacter has undergone significant taxonomic modification over the last 30yrs. It’s most important representative is Acinetobacter baumannii and other species such as-Acinetobacter lwoffii, Acinetobacter haemolyticus and Acinetobacter johnsonii are rarely isolated from patients. Acinetobacter species are opportunistic pathogens predominantly found in immunocompromised patients. They are widespread in nature, and regarded as commensal microbes of human skin and respiratory tract, however, they may cause serious infections, such as endocarditis, urinary tract infections, pneumonia, wound infections, meningitis, and septicemia, especially in individuals with impaired host defenses. The increased risk of infection is associated...
with the severity of patient’s illness, length of exposure to invasive devices and procedures, increased risk of patient contact with health care personnel and length of stay in ICU. In addition to infection among hospitalised patients, community acquired Acinetobacter infection is increasingly reported. An increase in antibiotic resistance among isolates of the organism during recent years has made these infections difficult to treat. Acinetobacter species are becoming increasingly resistant to nearly all routinely prescribed antimicrobial agents, including aminoglycosides, fluoroquinolones, and broad-spectrum β-lactams. The majority of strains are resistant to cephalosporin class of antimicrobials, whereas the resistance to carbapenems is increasingly reported.

The objective of the study is to determine the prevalence of the Acinetobacter infections and antibiotic sensitivity pattern of Acinetobacter species isolated from various clinical samples collected from patients attending Regional Institute of Medical Sciences Hospital.

METHODS

This study was conducted in the Department of Microbiology, Regional Institute of Medical Sciences, Imphal, Manipur, and included Acinetobacter species isolated from various clinical samples over a period of two years (October 2014 to September 2016). A total of 9979 clinical samples such as pus, urine, blood, catheter tips, tracheal aspirate, sputum and other body fluids were collected from patients attending OPD, admitted in ICU and different wards of hospital. The samples received in the laboratory were inoculated on 5% Sheep Blood Agar and Mac Conkey agar and incubated overnight aerobically at both 37°C. All isolates obtained were further processed and identified by routine microbiological and biochemical tests.

In case of urine samples, the isolates were subjected to biochemical tests only if the colony count was significant (>10^5 CFU/ml). Genus Acinetobacter was identified by characteristic colonies (Non Lactose-fermenting, glistening, small mucoid colonies), Gram staining pattern as Gram negative cocccobacilli, Motility as non-motile, and standard biochemical reactions (Catalase, oxidase, oxidation-fermentation test, indole production, citrate utilization, urease activity, reaction in triple sugar iron medium), speciation of Acinetobacter (A. baumannii and A. Iwoffii) was done on the basis of glucose oxidation (of test) and citrate utilization test. Antibiotic susceptibility testing was performed for each isolated by Kirby-Bauer disc diffusion method on Mueller-Hinton agar using 0.5 MacFarland turbidity standard and comparing zone sizes with control strain Pseudomonas aeruginosa ATCC 27853. The antimicrobial agents used were-ceftazidime (30μg), cefepime (30μg), ceftazidime and clavulanic acid, piperacillin-tazobactam (100μg/10μg), imipenem (10μg), meropenem (10μg), gentamicin (10μg), amikacin (30μg), cotrimoxazole (25μg), ciprofloxacin (5μg), levofloxacin, norfloxacin (30μg) and nitrofurantoin (300) (for urinary isolates), and colistin (10μg). Antibiotic susceptibility results were interpreted by measuring the zone diameters produced and correlating them with the CLSI standards. ESBL production was tested using the double-disc approximation method using ceftazidime and ceftazidime-clavulanic acid discs. All the analysis was performed using simple percentage method.

### RESULTS

During the study period, out of 9979 specimens received from hospital 3715 were positive for bacterial growth of which 111 (2.9%) were culture positive for Acinetobacter spp. Among all the 111 isolates, 109 (98.2%) are Acinetobacter baumannii and 2 (1.8%) are Acinetobacter Iwoffii. Table 1 shows the distribution of the isolates in various clinical samples. Maximum isolates were isolated from urine samples 36 (32.4%).

| Table 1: Isolation from different samples. |
|------------------------------------------|
| Clinical samples | No. of isolates (%) |
|------------------|---------------------|
| Pus              | 15(13.5%)           |
| Urine            | 36(32.4%)           |
| Swab             | 12(10.8%)           |
| Sputum           | 24(21.6%)           |
| Blood            | 7(6.3%)             |
| Tracheal aspirate| 12(10.8%)           |
| Catheter tube tips| 3(2.7%)            |
| Drain            | 2(1.8%)             |

Figure 1 shows that Acinetobacter infection mainly occurred in population aging between 41-60 yrs. Gender ratio was 1.2:1 (Female:Male) thus, a slight female preponderance was observed in our study. Highest isolates were isolated from wards 63 (56.7%) followed by OPD and ICU as shown in (Figure 2), giving a probability of increased hospital acquired infections.
Sensitivity pattern of *Acinetobacter* species to different antimicrobials showed higher resistance to ceftazidime 80.1% and ceftadizime 74.8% and lower resistance was observed to drugs gentamicin 20.7%. Resistance pattern for other drugs was co-trimazoxole-55%, piperacillin/tazobactum 50.5%, ceftazidime and clavulnic acid 61.2%, amikacin 24.3%, ciprofloxacin 45.9%, levoflaxacin 44.1%, imipenem 25.3%, meropenem 29.7%, nitrofurantoin 55.5%, norfloxacin 58.3% as shown in (Table 2). None of the isolates was resistant to colistin. Almost all the isolates showed in-vitro resistance to one or more of the antibiotics mentioned earlier.

Out of 111 isolates, 69 (62.1%) were MDR (Isolates resistant to resistance at least one agent in 3 or >3 different classes of antibiotics). Maximum resistance was observed in *Acinetobacter baumannii* was found to be more resistant than *Acinetobacter lwofii*, therefore maximum resistance was observed in ICU isolates followed by Ward and OPD isolates where *A. baumannii* was more prevalent (Table 3).

**Figure 2: Distribution of isolates from wards, ICU, OPD.**

**Table 2: Antibiotic resistance pattern of the *Acinetobacter* species isolates.**

| Antibiotics               | Resistant isolates (% Resistance) | Sensitive isolates (% Sensitivity) |
|---------------------------|----------------------------------|-----------------------------------|
| Imipenem                 | 28(25.3%)                         | 83(74.7%)                         |
| Meropenem                | 33(29.7%)                         | 78(70.3%)                         |
| Piperacillin/tazobactum  | 56(50.5%)                         | 55(49.5%)                         |
| Ceftazidime and clavulnic acid | 68(61.2%)     | 43(38.8%)                         |
| Ceftazidime              | 83(74.8%)                         | 28(25.2%)                         |
| Ceftipime                | 89(80.1%)                         | 22(19.9%)                         |
| Co-trimazoxole           | 61(55%)                           | 50(45%)                           |
| Gentamicin               | 23(20.7%)                         | 88(79.3%)                         |
| Amikacin                 | 27(24.3%)                         | 84(75.7%)                         |
| Ciprofloxacin            | 51(45.9%)                         | 60(54.1%)                         |
| Levoflaxacin             | 49(44.1%)                         | 62(55.9%)                         |
| Norflaxacin (n=36)       | 21(58.3%)                         | 15(41.7%)                         |
| Nitrofurantoin (n=36)    | 20(55.5%)                         | 16(44.5%)                         |
| Colistin                 | 0(0%)                             | 111(100%)                         |

**Table 3: Comparison between antibiotic resistances of *Acinetobacter* species isolated from ICU, Wards and OPD.**

| Name of antibiotic | Total no. of resistant isolates | ICU (n=20) n (%) | Wards (n=63) n (%) | OPD (n=28) n (%) |
|--------------------|---------------------------------|------------------|--------------------|------------------|
| Imipenem           | 28                              | 10(50%)          | 18(28.6%)          | 0(0%)            |
| Meropenem          | 33                              | 11(55%)          | 17(30%)            | 5(17.8%)         |
| Piperacillin/tazobactum | 56                          | 17(85%)         | 35(55.5%)          | 4(14.3%)         |
| Ceftazidime and clavulnic acid | 68                        | 16(80%)         | 47(74.6%)          | 5(17.8%)         |
| Ceftazidime        | 83                              | 20(100%)         | 52(82.5%)          | 11(39.3%)        |
| Ceftipime          | 89                              | 20(100%)         | 54(85.7%)          | 15(53.6%)        |
| Co-trimazoxale     | 61                              | 18(90%)          | 37(58.7%)          | 6(21.4%)         |
| Gentamicin         | 23                              | 10(50%)          | 13(20.6%)          | 0(0%)            |
| Amikacin           | 27                              | 12(60%)          | 15(23.8%)          | 0(0%)            |
| Ciprofloxacin      | 51                              | 18(90%)          | 29(46%)            | 4(14.3)          |
| Levoflaxacin       | 49                              | 15(75%)          | 28(44.4%)          | 6(21.4%)         |
| Norflaxacin (n=36) | 21                              | 2(100%) n=2      | 12(63.2%) n=19     | 7(46.7%) n=15    |
| Nitrofurantoin (n=36) | 20                          | 2(100%) n=2     | 10(52.6%) n=19     | 8(53.3%) n=15    |
| Colistin           | 0                               | 0(0%)            | 0(0%)              | 0(0%)            |

**DISCUSSION**

In our study, from 3715 bacterial isolates, 111 (2.9%) *Acinetobacter* species were obtained. Similar prevalence of 3% and 3.36% of total organisms isolated was reported by Dash et al in Odisha and Gupta et al in Pune. Higher prevalence rates of 14% and 9.6% was reported by Mostofi et al, in Tehran, Iran and Joshi et al in Pune. In the present study maximum isolates were isolated from wards 63 (56.7%). This is probably related...
to increasingly invasive diagnostic procedures used, greater quantity of broad spectrum antimicrobials used and prolonged duration of stay in hospital.5,6

The higher isolation rates 36 (32.4%) of Acinetobacter spp from the Urine samples are not in agreement with the results reported previously in other studies where higher isolation rates were most often from respiratory samples.6 According to literature, amongst Acinetobacter spp, commonest species isolated in human clinical specimens is A. baumannii.2 We also observed that 109 (98.2%) isolates were A. baumannii whereas remaining 2 (1.8%) isolates were A. Iwoffii.

In the present study, Acinetobacter species were found to be resistant to most commonly used antibiotics. Acinetobacter isolates were extremely resistant to Cefepime (80.1%) and ceftazidime (74.8%) which correlates with the studies by Guckan R et al.17 Resistance to levofloxacin is found less in comparison to other fluoroquinolones in our study and similar finding was also found by Bhattacharya et al in their study.18 Resistance towards imipenem and Meropenem was recorded to be 25.3% and 29.7% respectively. A study by Dash et al also reported more resistance towards Meropenem (22%) as compared to imipenem (19%).3 No resistance was seen in Colistin in our study which is similar to the study published by Dash et al and Shareek et al, whereas isolates were sensitive to colistin.5,19

Out of total isolates 69 (62.1%) were multidrug resistant (MDR) in our study. The other studies conducted by Dash et al, in Odisha and Rekha et al in Kolar, Karnataka reported MDR isolates to be 55% and 74% respectively.5,6 Bhattacharya et al, Gupta et al, and Mostofi et al, reported MDR isolates to be 29%; 40% and 54% respectively.8,11,14 Maximum resistance in our study was observed in ICU isolates in comparison to wards and opd. In ICUs most, sensitive drug was colistin (100%) followed by imipenem (50%) and gentamicin (50%). Acinetobacter appears to have a propensity to develop antibiotic resistance extremely rapidly, perhaps as a consequence of its long term evolutionary exposure to antibiotic producing organisms in soil environment. The emergence of antibiotic resistant strains in ICU is because of higher use of antimicrobial agents per patient and per surface area.14

Notably, our findings show that Gentamicin and Amikacin is effective against Acinetobacter spp. showing 20.7% and 24.3% resistance respectively which can be a cost effective therapeutic option against Acinetobacter isolates, especially in this part of India. Susceptibilities of Acinetobacter against antimicrobials are considerably different among countries, centers and even among different wards of the same hospital. Therefore, such types of local surveillance studies are around important in deciding the most adequate therapy for Acinetobacter infections.20

CONCLUSION

Acinetobacter is nowadays a common threat in hospital acquired infections especially in critically ill patients admitted to ICU. Acinetobacter species in our study were found to be resistant to most commonly used antibiotics. It is a great challenge for the physicians to treat MDR Acinetobacter spp. which is independently associated with high mortality, emphasizing the need for aggressive infection control strategies. Emergence of carbapenem resistance is worrisome. Only drug which is sensitive is colistin. Though the organism has developed multidrug resistance, it has largely remained susceptible to disinfectants and antiseptics. Thus, the prevention involves aseptic care of vascular catheters and endotracheal tubes, proper disinfection of surfaces with which the patient comes in contact and through hand hygiene of health care workers. To avoid resistance, antibiotics should be used judiciously and empirical therapy should be determined for each hospital according to the resistance rates of the hospital.

ACKNOWLEDGEMENTS

Authors would like to thank technical staffs of Regional Institute of Medical Science, Imphal for their help in performing different laboratory investigation.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Gautam V, Singhal L, Ray P. Burkholoderia cepacia complex: Beyond Pseudomonas and Acinetobacter. Ind J Med Microbiol. 2011;29:4-12.
2. Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, et al. Non-fermenting Gram negative bacilli In: Koneman’s color Atlas and textbook of Diagnostic Microbiology. 6th ed. USA: Lippincott Williams and Wilkins Company; 2006:305-91.
3. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9:148-65.
4. Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. J Crit Care Med. 2001:29:64-8.
5. Dash M, Padhi S, Patnaik S, Mohanty I, Misra P. Frequency, risk factors and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India. Avicenna J Med. 2013;3(4):97-102.
6. Rekha S, Gokul BN, Beena PM, Prasad SR. Multidrug resistant Acinetobacter isolates from patients admitted at Kolar. J Clin Biomed Sci. 2011;1:3-7.
7. Lyytikainen O, Koljalg S, Harma M, Vuopio-Varkila J. Outbreak caused by two multi-resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. J Hosp Infect. 1995;31:41-54.
8. Tille PM. Bailey and Scott’s Diagnostic Microbiology. 13th edition. St. Louis, Missouri: Elsevier; 2014:193-231.
9. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493-6.
10. Clinical Laboratory Standards Institutes (CLSI). Performance standards for antimicrobial susceptibility testing. 26th ed. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute. 2016 Jan;36(1):40-256
11. Bradford PA. Extended spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933-51.
12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug resistant, extensively drug resistant and pandrug resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.
13. Adams-Haduch JM, Paterson DL, Sidjabat HE, Pascullle AW, Potoski BA, Muto CA, et al. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother. 2008;52:3837-43.
14. Gupta N, Gandham N, Jadhav S, Mishra RN. Isolation and identification of Acinetobacter species with special reference to antibiotic resistance. J Nat Sc Biol Med. 2015;6:159-62.
15. Mostofi S, Mirnejad R, Masjedian F. Multi-drug resistance in Acinetobacter baumannii strains isolated from clinical specimens from three hospitals in Tehran-Iran. Afr J Microbiol Res. 2011;5:3579-82.
16. Joshi SG, Litake GM, Satpute MG, Telang NV, Ghole VS, Niphadkar KB. Clinical and demographic features of infection caused by Acinetobacter species. Ind J Med Sci. 2006;60:351-60.
17. Guckan R, Kilinc C, Demir AD, Capraz A, Yanik K. Antimicrobial susceptibility of acinetobacter baumannii complex isolated from different clinical samples in a tertiary care hospital. J Antibiotics Research. 2015;01(01).
18. Bhattacharyya S, Bhattacharyya I, Rit K, Mukhopadhyay PK, Dey JB, Ganguly U, et al. Antibiogram of Acinetobacter spp. isolated from various clinical specimens in a tertiary care hospital, West Bengal, India. Biomed Res. 2013;24:43-6.
19. Shareek PS, Sureshkumar D, Ramagopalakrishnan S, Ramasubramanian V, Abdul Ghafur K, Thirumarayanan MA. Antibiotic sensitivity pattern of blood isolates of Acinetobacter species in a tertiary care hospital: A retrospective analysis. Am J Infect Dis. 2012;8:65-9.
20. Nahar A, Anwar S, Saleh AA, Miah RA. Isolation of Acinetobacter species and their antimicrobial resistance pattern in an Intensive Care Unit (ICU) of a tertiary care hospital in Dhaka, Bangladesh. Bangladesh J Med Microbiol. 2012;06(01):3-6.

Cite this article as: Saha S, Devi KM, Damrolien S, Devi KS. A study of Acinetobacter infections in a tertiary care hospital in Northeast India. Int J Res Med Sci 2018;6:2076-80.